Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management

Table 2

Summery of topical treatment in the prevention of EGFRI-induced skin toxicity.

Author; Year	Type of study	EGFRI agent	Patients; (𝑛)	Topical agent	Objective	Results	Quality of life
Scope et al. 2007 [35]	RCT	Cetuximab	48	Tazarotene applied to half of the face	To decrease or prevent skin toxicity	No difference in the two groups	32.6% discontinued tazarotene due to significant irritation
Ocvirk et al. 2008 [41]	Uncontrolled trial	Cetuximab	43	Vitamin K1 cream	To decrease or prevent skin toxicity	65% developed skin toxicity, limited to merely grade 1 and 2	NA
Scope et al. 2009 [40]	RCT	Cetuximab	24	Pimecrolimus applied to half of the face	To decrease or prevent skin toxicity	Decrease lesion count in pimecrolimus treated side; 𝑃 value < 0.001 in week 2; 𝑃 value = 0.02 in week 5	NA
Jatoi et al. 2010 [42]	RCT	Multiple	110	Sunscreen with SPF of 60	To decrease or prevent skin toxicity	No difference in rash incidence (72% versus 80% 𝑃=1.00) or severity	No difference in quality of life

NA: not assessed.